Want to see ZNTL full AI Analyst Report?
ZNTL Stock Chart & Stats
$3.88
-$0.17(-5.69%)
At close: 4:00 PM EST
$3.88
-$0.17(-5.69%)
Day’s Range― - ―
52-Week Range$1.21 - $6.95
Previous CloseN/A
Volume750.15K
Average Volume (3M)1.09M
Market Cap
$351.23M
Enterprise Value$209.01
Total Cash (Recent Filing)$174.61M
Total Debt (Recent Filing)$37.69M
Price to Earnings (P/E)―
Beta3.36
Next Earnings
Nov 11, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding94,671,910
10 Day Avg. Volume925,373
30 Day Avg. Volume1,094,076
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.83Price Target Upside127.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressEnrollment completion and initiation of a confirmatory Phase 3 study advance azenosertib toward pivotal evidence and potential approval, creating identifiable development milestones and a clearer path to future commercialization.
Encouraging Clinical EfficacyReported response and progression-free-survival data support azenosertib’s therapeutic potential in difficult-to-treat ovarian cancer. The results may broaden its use across monotherapy and taxane-combination settings if confirmed in later trials.
Extended Development RunwayA substantial cash position and stated runway into late 2027 give Zentalis time to execute pivotal studies, pursue regulatory filings and develop manufacturing capabilities without immediate reliance on another financing.
Bears Say
Persistent UnprofitabilityThe company has not established recurring commercial revenue, while its cost base remains well ahead of commercialization. Renewed widening of TTM losses indicates profitability is still dependent on successful clinical development and eventual product approval.
High Cash BurnNegative operating and free cash flow show that research and development expenses translate into substantial cash outflows. If the current burn persists, Zentalis may require additional capital before generating internally funded operations.
Shareholder DilutionThe large equity financing strengthens liquidity but expands the share count and reduces existing investors’ ownership percentage. Repeated reliance on equity capital could remain a structural cost while the pipeline is pre-commercial.
Zentalis Pharmaceuticals News
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.21 and its highest was $6.95 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $351.23M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.49 by -$0.1.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.59.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 94,671,910 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.49. Following the earnings report the stock price went down -15.6%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentalis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.83 (127.66% Upside)
$8.83 (127.66% Upside)
Blogger Sentiment
Bullish
ZNTL Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 336.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 14.6%
Last 30 Days ▲ 14.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
ZNTL Stock 12 Month Forecast
Average Price Target
$8.83
▲(127.66% Upside)
Technical Analysis
MacroGenics
―
VistaGen Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
Ownership Overview
27.51% Insiders
5.08% Mutual Funds
19.34% Other Institutional Investors
40.68% Public Companies and
Individual Investors